NAT10 is Upregulated in Hepatocellular Carcinoma and Enhances Mutant P53 Activity

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2017 Sep 2

PMID 28859621

Citations 45

Authors

Qijiong Li

Xiaofeng Liu

Kemin Jin

Min Lu

Chunfeng Zhang

Xiaojuan Du

Baocai Xing

Affiliations

Soon will be listed here.

Abstract

Background: N-acetyltransferase 10 (NAT10) is a histone acetyltransferase which is involved in a wide range of cellular processes. Recent evidences indicate that NAT10 is involved in the development of human cancers. Previous study showed that NAT10 acetylates the tumor suppressor p53 and regulates p53 activation. As Tp53 gene is frequently mutated in hepatocellular carcinoma (HCC) and associates with the occurrence and development of HCC, the relationship between NAT10 and HCC was investigated in this study.

Methods: Immunohistochemistry (IHC) and western blot analysis were performed to evaluate the NAT10 expression in HCC. Immunoprecipitation experiments were performed to verify the interaction of NAT10 with mutant p53 and Mdm2. RNA interference and Western blot were applied to determine the effect of NAT10 on mutant p53. Cell growth curve was used to examine the effect of NAT10 on HCC cell proliferation.

Results: NAT10 was upregulated in HCC and increased NAT10 expression was correlated with poor overall survival of the patients. NAT10 protein levels were significantly correlated with p53 levels in human HCC tissues. Furthermore, NAT10 increased mutant p53 levels by counteracting Mdm2 action in HCC cells and promoted proliferation in cells carrying p53 mutation.

Conclusion: Increased NAT10 expression levels are associated with shortened patient survival and correlated with mutant p53 levels. NAT10 upregulates mutant p53 level and might enhance its tumorigenic activity. Hence, we propose that NAT10 is a potential prognostic and therapeutic candidate for p53-mutated HCC.

Citing Articles

Acetyltransferase NAT10 promotes gastric cancer progression by regulating the Wnt/β-catenin signaling pathway and enhances chemotherapy resistance.

Chen Y, Yang J, Du Y, Yan Z, Gao J, Zhang H Discov Oncol. 2025; 16(1):173.

PMID: 39945932 PMC: 11825422. DOI: 10.1007/s12672-025-01917-5.

Biological function and mechanism of NAT10 in cancer.

Han Y, Zhang X, Miao L, Lin H, Zhuo Z, He J Cancer Innov. 2025; 4(1):e154.

PMID: 39817252 PMC: 11732740. DOI: 10.1002/cai2.154.

RNA N4-acetylcytidine modification and its role in health and diseases.

Wang Q, Yuan Y, Zhou Q, Jia Y, Liu J, Xiao G MedComm (2020). 2025; 6(1):e70015.

PMID: 39764566 PMC: 11702397. DOI: 10.1002/mco2.70015.

Advances of NAT10 in diseases: insights from dual properties as protein and RNA acetyltransferase.

Xiao B, Wu S, Tian Y, Huang W, Chen G, Luo D Cell Biol Toxicol. 2024; 41(1):17.

PMID: 39725720 PMC: 11671434. DOI: 10.1007/s10565-024-09962-6.

A review of current developments in RNA modifications in lung cancer.

Zhang S, Liu Y, Liu K, Hu X, Gu X Cancer Cell Int. 2024; 24(1):347.

PMID: 39456034 PMC: 11515118. DOI: 10.1186/s12935-024-03528-6.

References

Cheok C, Verma C, Baselga J, Lane D . Translating p53 into the clinic. Nat Rev Clin Oncol. 2010; 8(1):25-37. DOI: 10.1038/nrclinonc.2010.174. View

Tan T, Miow Q, Huang R, Wong M, Ye J, Lau J . Functional genomics identifies five distinct molecular subtypes with clinical relevance and pathways for growth control in epithelial ovarian cancer. EMBO Mol Med. 2013; 5(7):1051-66. PMC: 3721473. DOI: 10.1002/emmm.201201823. View

Esser C, Scheffner M, Hohfeld J . The chaperone-associated ubiquitin ligase CHIP is able to target p53 for proteasomal degradation. J Biol Chem. 2005; 280(29):27443-8. DOI: 10.1074/jbc.M501574200. View

Dittmer D, Pati S, Zambetti G, Chu S, Teresky A, Moore M . Gain of function mutations in p53. Nat Genet. 1993; 4(1):42-6. DOI: 10.1038/ng0593-42. View

Kandoth C, McLellan M, Vandin F, Ye K, Niu B, Lu C . Mutational landscape and significance across 12 major cancer types. Nature. 2013; 502(7471):333-339. PMC: 3927368. DOI: 10.1038/nature12634. View

Doyle B, Morton J, Delaney D, Ridgway R, Wilkins J, Sansom O . p53 mutation and loss have different effects on tumourigenesis in a novel mouse model of pleomorphic rhabdomyosarcoma. J Pathol. 2010; 222(2):129-37. DOI: 10.1002/path.2748. View

Issaeva N, Bozko P, Enge M, Protopopova M, Verhoef L, Masucci M . Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med. 2004; 10(12):1321-8. DOI: 10.1038/nm1146. View

Yan W, Liu G, Scoumanne A, Chen X . Suppression of inhibitor of differentiation 2, a target of mutant p53, is required for gain-of-function mutations. Cancer Res. 2008; 68(16):6789-96. PMC: 2597213. DOI: 10.1158/0008-5472.CAN-08-0810. View

Leroy B, Fournier J, Ishioka C, Monti P, Inga A, Fronza G . The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis. Nucleic Acids Res. 2012; 41(Database issue):D962-9. PMC: 3531172. DOI: 10.1093/nar/gks1033. View

10.

Bykov V, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, Chumakov P . Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med. 2002; 8(3):282-8. DOI: 10.1038/nm0302-282. View

11.

Sell S . Mouse models to study the interaction of risk factors for human liver cancer. Cancer Res. 2003; 63(22):7553-62. View

12.

Vousden K, Prives C . Blinded by the Light: The Growing Complexity of p53. Cell. 2009; 137(3):413-31. DOI: 10.1016/j.cell.2009.04.037. View

13.

Morton J, Timpson P, Karim S, Ridgway R, Athineos D, Doyle B . Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. Proc Natl Acad Sci U S A. 2009; 107(1):246-51. PMC: 2806749. DOI: 10.1073/pnas.0908428107. View

14.

Freed-Pastor W, Prives C . Mutant p53: one name, many proteins. Genes Dev. 2012; 26(12):1268-86. PMC: 3387655. DOI: 10.1101/gad.190678.112. View

15.

Li D, Marchenko N, Moll U . SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis. Cell Death Differ. 2011; 18(12):1904-13. PMC: 3170683. DOI: 10.1038/cdd.2011.71. View

16.

Weissmueller S, Manchado E, Saborowski M, Morris 4th J, Wagenblast E, Davis C . Mutant p53 drives pancreatic cancer metastasis through cell-autonomous PDGF receptor β signaling. Cell. 2014; 157(2):382-394. PMC: 4001090. DOI: 10.1016/j.cell.2014.01.066. View

17.

Liu H, Ling Y, Gong Y, Sun Y, Hou L, Zhang B . DNA damage induces N-acetyltransferase NAT10 gene expression through transcriptional activation. Mol Cell Biochem. 2006; 300(1-2):249-58. DOI: 10.1007/s11010-006-9390-5. View

18.

Soussi T, Wiman K . Shaping genetic alterations in human cancer: the p53 mutation paradigm. Cancer Cell. 2007; 12(4):303-12. DOI: 10.1016/j.ccr.2007.10.001. View

19.

Yu X, Vazquez A, Levine A, Carpizo D . Allele-specific p53 mutant reactivation. Cancer Cell. 2012; 21(5):614-625. PMC: 3366694. DOI: 10.1016/j.ccr.2012.03.042. View

20.

Chi Y, Haller K, Peloponese Jr J, Jeang K . Histone acetyltransferase hALP and nuclear membrane protein hsSUN1 function in de-condensation of mitotic chromosomes. J Biol Chem. 2007; 282(37):27447-27458. DOI: 10.1074/jbc.M703098200. View